A Randomized, Open-label, Single Dose, Two-way Crossover Study to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
Latest Information Update: 22 Apr 2022
Price :
$35 *
At a glance
- Drugs BR 2008 (Primary)
- Indications Lung cancer
- Focus Pharmacokinetics
- Sponsors Boryung Pharmaceutical
- 19 Apr 2022 Status changed from active, no longer recruiting to completed.
- 18 Nov 2021 Planned End Date changed from 22 Dec 2021 to 14 Jan 2022.
- 18 Nov 2021 Planned primary completion date changed from 4 Nov 2021 to 29 Nov 2021.